Compare ITT & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | DGX |
|---|---|---|
| Founded | 1920 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2B | 21.0B |
| IPO Year | 1994 | 1996 |
| Metric | ITT | DGX |
|---|---|---|
| Price | $191.45 | $200.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $216.45 | $214.38 |
| AVG Volume (30 Days) | 606.1K | ★ 623.9K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | 0.73% | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 0.89 | ★ 2.24 |
| Revenue | $3,938,500,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $32.87 | $7.53 |
| Revenue Next Year | $9.78 | $3.77 |
| P/E Ratio | $217.20 | ★ $87.54 |
| Revenue Growth | 8.48 | ★ 11.78 |
| 52 Week Low | $149.02 | $164.65 |
| 52 Week High | $225.26 | $213.50 |
| Indicator | ITT | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 63.13 |
| Support Level | $177.56 | $194.09 |
| Resistance Level | $196.82 | $212.16 |
| Average True Range (ATR) | 4.26 | 3.82 |
| MACD | -0.22 | 0.83 |
| Stochastic Oscillator | 24.49 | 90.02 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.